Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated ...

ATLANTA, Georgia — A novel investigational therapeutic agent appears to be an effective and safe treatment option for patients with chronic lymphocytic leukemia (CLL). According to 2 new studies ...

These investigators assessed the poorly understood biology and genetics that underlie the transformation of CLL to RS and that impedes progress against this aggressive malignancy. TP53 Abnormalities ...

Recent years have brought more targeted agents to the frontline treatment for patients with chronic lymphocytic leukemia. Strides have been made for the frontline treatment of patients with chronic ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Please provide your email address to receive an email when new articles are posted on . Novel targeted therapies have become standard treatment for chronic lymphocytic leukemia due to their ability to ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial First, patient-level correlation was confirmed using ...

Please provide your email address to receive an email when new articles are posted on . Time-limited, dual B-cell receptor inhibitor therapy seems promising in treatment-naive and relapsed/refractory ...

Designation supported by promising safety and efficacy data from Phase 1/2 study in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic ...